Table 4.
Serious adverse events and non-serious adverse events observed/reported by more than one participant over the course of the study
| Ophthalmic events | Total number | Serious | Non-ophthalmic events | Total | Serious |
|---|---|---|---|---|---|
| Cataract | 6 | Cold/flu symptoms | 10 | 0 | |
| Visual disturbance (spots/floaters) | 6 | Hypo/hyperglycemia | 4 | 2 | |
| Subcutaneous hemorrhage | 7 | Chest infection | 4 | 2 | |
| Post-injection pain | 2 | Renal failure | 2 | 1 | |
| Stinging eyes | 2 | Allergy NOS | 2 | 1 | |
| Gastroenteritis | 2 | 1 | |||
| Vitreous hemorrhage | 2 | 2 | Cerebrovascular accident | 1 | 1 |
| Congestive cardiac failure | 1 | 1 | |||
| Myocardial infarction | 1 | 1 | |||
| Angina exacerbation | 1 | 1 | |||
| Hypocalcemia | 1 | 1 | |||
| Respiratory failure | 1 | 1 |
NOS Not otherwise specified